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Abstract
 .  .The GH cell line, a bipotential cell line secreting both prolactin PRL and growth hormone GH , is a useful model for3
investigating GHrPRL cell lineage differentiation and anterior pituitary adenoma formation. In this study, we investigated
the ganglioside composition of GH cells and identified two fucogangliosides as the major gangliosides expressed by these3
 .cells. Analyses by DEAE-Sephadex A-25 and thin-layer chromatography TLC revealed that the GH cells contained two3
major gangliosides, designated FG1 and FG2, respectively. Their structures were identified by fast atom bombardment mass
spectrometry and proton nuclear magnetic resonance spectrometry: FG1 is IV 2 Fuca ,II 3NeuAc–GgOse Cer and FG2 is4
IV 2 Fuca ,IV 3Gala ,II 3NeuAc–GgOse Cer. Expression of these fucogangliosides was enhanced by chronic treatment with4
 .  .  .17b-estradiol 1 nM , epidermal growth factor 10 nM and insulin 300 nM , which induced differentiation of GH cells to3
normal PRL-secreting cells. Interestingly, immunocytochemistry and flow cytometry revealed that the increased expression
of these gangliosides reflected a quantitative change inside the cells but not on the cell surface. These results suggest that
the intracellular distribution of fucogangliosides is closely related to the differentiation of GH cells. q 1998 Elsevier3
Science B.V.
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1. Introduction
Gangliosides are constituents of plasma mem-
branes in virtually all vertebrate tissues and are also
present in body fluids. They are located almost exclu-
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sively in the outer leaflet of plasma membranes, and
have been implicated in many cell surface phenom-
ena, including cellular adhesion, cellular communica-
tion, and modulation of receptor responses. The gan-
glioside composition of the cells changes dramati-
cally during cellular differentiation or oncogenic
w xtransformation 1–3 . Several lines of evidence indi-
cate that growth factors modulate the cell surface
ganglioside composition in clonal cell lines. Pilking-
w xton et al. 4 have shown that basic fibroblast growth
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 .  .factor bFGF and epidermal growth factor EGF ,
 .but not platelet-derived growth factor PDGF , induce
increases in the number of cells that bind a mono-
 .clonal antibody mAb , A2B5, that recognizes
polysialogangliosides, in cloned neoplastic astrocytes,
w xand Gillard et al. 5 found that interferon-g induces
the redistribution of glycosphingolipids from the
plasma membrane to intracellular organelles. The
results of these studies indicate that still unknown
molecular mechanisms that are modified by growth
factors and hormones in the course of cell differentia-
tion affect the membrane composition and intra-
cellular distribution of gangliosides.
There are at least five types of hormone-secreting
cells in the anterior pituitary gland, and each of them
synthesizes and secretes distinctive hormones. GH 3
cells, which are radiation-induced rat pituitary tumor
 .cells that secrete both growth hormone GH and
 .prolactin PRL , provide a suitable model for the
w xstudy of GHrPRL cell lineage 6,7 . Treatment of
GH C cells, a subclone derived from GH cells,4 1 3
 .with a combination of 17b-estradiol E , EGF and2
insulin induces differentiation into PRL-secreting
cells, characterized by increased release and intra-
w xcellular storage of PRL 8 .
The composition of the gangliosides in the anterior
pituitary gland and GH cells has not been analyzed,3
but some studies using mAbs against glycosphin-
golipids have indicated a possible correlation be-
tween the expression of specific gangliosides and
w xanterior pituitary cell differentiation 9,10 . Thus, an-
alyzing the ganglioside composition of GH cells3
may provide new insights into the differentiation of
the GHrPRL cell lineage. In this study, we identified
a Gal–fucosyl GM1 and fucosyl GM1 as major gan-
glioside components of GH cells, and found that3
expression of these fucogangliosides was enhanced in
differentiated GH cells.3
2. Materials and methods
2.1. Materials
DEAE-Sephadex A-25 was purchased from Phar-
 .macia Fine Chemicals Uppsala, Sweden and high-
 .performance thin layer chromatography HPTLC
 . plates silica gel 60 were from E. Merck Darmstadt,
.  .Germany . EGF from mouse submaxillary glands
 .and insulin from bovine pancreas were from Sigma
 .Diagnostics St. Louis, MO, USA . Fucosyl GM1
w x 2was purified from boar testis 11 and IV Fuca ,
3 3  .IV Gala ,II NeuGc–GgOse Cer M12 was a kind4
w xgift from Nohara et al. 12 . All other reagents were
of analytical grade and were obtained from commer-
cial sources.
2.2. Cell culture
GH cells were maintained as monolayers in F-103
 .Nutrient Medium Ham supplemented with 15%
horse serum and 2.5% fetal calf serum at 378C in a
humidified atmosphere of 5% CO and 95% air. The2
cells were subcultured in 100-mm Petri dishes Costar,
. 5Cambridge, MA at a density of 5=10 cells per
dish. Two days after plating, the medium was changed
 . to fresh medium containing EGF 10 nM , E 12
.  .nM , and insulin 300 nM to obtain hormone-treated
GH cells. The medium was changed on day 4, and3
both hormone-treated and untreated cells were col-
lected on day 6. To extract the glycolipids, the GH 3
cells were scraped from the dish with a rubber police-
man and suspended in Buffer A 140 mM NaCl, 5
mM KCl, 0.7 mM Na HPO , 25 mM HEPES, pH2 4
.7.3 . The final pellets obtained by centrifugation were
stored at y208C until used.
2.3. Separation of gangliosides for TLC-analysis
The ganglioside fractions were isolated from both
hormone-treated and untreated GH cells and ana-3
lyzed by TLC as described previously, with slight
w xmodifications 13,14 . Briefly, total lipids were ex-
tracted with 10 volumes each of chloro-
 .formrmethanol, 2:1, 1:1 and 1:2 vrv , and the
combined lipid extract was evaporated to dryness.
The total lipid extract was dissolved in solvent A
 .chloroformrmethanolrwater, 30:60:8, vrvrv and
applied to a DEAE-Sephadex A-25 column. The
column was washed successively with solvent A and
methanol, and the ganglioside fraction was eluted
with 0.05 M, 0.15 M and 0.45 M ammonium acetate
in methanol. Each fraction was monitored by HPTLC
developed with chloroformrmethanolr5 N ammo-
 .niar0.4% CaCl 55:50:4:6, vrvrvrv . Ganglioside2
fractions extracted from 5=105 GH cells were3
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separated in one lane on TLC plate. Glycolipids were
visualized by spraying the plate with orcinolrH SO2 4
reagent. The densitometric data was analyzed using
the software NIH Image, running on a Macintosh
computer.
2.4. Enzyme treatment
The mono-sialoganglioside fraction separated by
DEAE-Sephadex A-25 column chromatography was
treated with two different neuraminidases, from
Arthrobacter ureafaciens and Clostridium perfrin-
w xgens, by previously reported methods 14,15 . The
 .evaporated fraction 10–20 ng was added to the
reaction mixtures, which was either 0.1 unit of the
enzyme from A. ureafaciens in 120 ml of 10 mM
 .phosphate buffer pH 7.3 with 150 mg of sodium
taurodeoxycholate, or 0.1 unit of the enzyme from C.
perfringens in 70 ml of 40 mM sodium acetate buffer
 .pH 5.0 , and incubated at 378C for 16 h. The
products were applied to an LH-20 column to remove
w xthe salt 16 and analyzed by TLC with
resorcinolrHCl reagent for sialic acid detection and
orcinolrH SO reagent for the detection of asialo-2 4
structures.
2.5. Purification of gangliosides from differentiated
GH cells for structural analysis3
The total lipid extract obtained from 109 GH 3
cells as described in Section 2.3 was evaporated to
dryness and then partitioned according to the method
w xof Folch et al. 17 . After the lower phase had been¨
washed twice with the theoretical upper phase, the
combined upper phase was evaporated to dryness,
dialyzed against water, and then lyophilized. The
crude gangliosides thus obtained were dissolved in
 .chloroformrmethanolrwater 30:60:8, vrvrv and
then applied to a DEAE-Sephadex A-25 column.
After washing the column with methanol, acidic gly-
colipids were eluted with 0.2 M sodium acetate in
methanol. Following dialysis against water and
lyophilization, the isolation of FG1 and FG2 was
performed by high performance liquid chromatogra-
 . phy HPLC using a Silica-7 column 4.6=250
mm–4.6=150 mm, Nomura Chemical Co., Seta,
.Japan with a linear gradient elution from 5% to
80% solvent B isopropanolrn-hexaner3 N
.NH OHrwater, 850:25:75:150, vrvrvrv in solvent4
A isopropanolrn-hexaner3 N NH OHrwater,4
.660:480:60:0, vrvrvrv . Two peaks, detected by
monitoring the absorbance at 210 nm, were collected
and subjected to ganglioside analysis as described in
Sections 2.6 and 2.7.
2.6. Mass spectrometry
 .Negative-ion fast atom bombardment FAB mass
spectrometry of the purified gangliosides was carried
 .out with a mass spectrometer JMS-HX 110, JEOL
w xusing triethanolamine as the matrix 12 . The acceler-
ating voltage was 8 kV, and the primary beam for
bombardment was 3.0 kV Xe0.
2.7. Nuclear magnetic resonance spectroscopy
 .Nuclear magnetic resonance NMR spectra were
 . w xobtained with a spectrometer GX-400, JEOL 18 .
 .The purified gangliosides 1 to 2 mg were dissolved
 .in 0.5 ml of dimethyl sulfoxide-d rD O 98:2, vrv6 2
containing tetramethyl silane, as described previ-
ously.
2.8. TLC immunostaining
The binding of mAbs against human blood group
 .B antigen Dako Japan, Kyoto, Japan and fucosyl
 w xGM1 CRD73-6 19 ; a kind gift from Dr. S.
.Kusunoki to gangliosides extracted from GH cells3
was analyzed by TLC immunostaining according to
w xpreviously described methods 20 . Briefly, the plates
were incubated with anti-human blood group B mAb
 .  .1:30 and CRD73-6 1:30 diluted in PBS containing
 .1% bovine serum albumin 1% BSA–PBS for 2 h
and then soaked in PBS. An avidin–biotin complex
staining kit, Vectorstain ABC kit Vector Laborato-
.ries, Burlingame, CA was used to detect bound
mAb, according to the manufacturer’s instructions.
The plates were exposed to the substrate solution
 .4-chloro-1-naphthol and H O for 3 to 5 min be-2 2
fore being washed with H O and dried to terminate2
development.
2.9. Flow cytometric analysis of GH cells3
Cell suspensions for immunological labeling of
cell surface gangliosides were centrifuged at 300=g
for 5 min, then resuspended at a density of 1–2=106
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Fig. 1. Morphological and physiological changes in GH cells3
induced by chronic treatment with E , EGF, and insulin. GH2 3
cells were observed by phase-contrast microscopy. The cells
 5.5=10 were seeded in 10-cm diameter Petri dishes. On day 2
after plating, 1 nM E , 10 nM EGF and 300 nM insulin were2
added, and the medium was replaced on day 6. Photographs were
taken on day 6 of the treatment. A and B, untreated control GH 3
 .  .cells: A phase-contrast; B immunostaining with anti-rat PRL
 .antiserum. C and D, hormone-treated GH cells: C phase-con-3
 .trast; D immunostaining with anti-rat PRL antiserum. Magnifi-
cation, =200.
cellsr50 ml in diluted primary antibodies and incu-
bated for 60 min at 48C. The cells were washed three
times with PBS containing 0.1% sodium azide and
1% BSA and then incubated in fluorescein-con-
 .jugated anti-mouse immunoglobulin Ig antibody
 .Cappel, West Chester, PA for 60 min at 48C. After
incubation, the cells were rinsed and analyzed using a
fluorescence activated cell sorter FACScan, Becton
.Dickinson Inc., San Jose, CA and Cell Quest soft-
ware running on a Macintosh computer.
2.10. Immunocytochemistry
GH cells were cultured on plastic coverslips3
Sumilon Celldesk, Sumitomo, Tokyo, Japan, Cat
.aMS-92130 . The medium was replace with fresh
medium with or without additives on days 2 and 6.
The cells were fixed with cold acetone and then
washed with PBS on day 7, and were stored at
y208C until used. The cells were incubated first in
0.01% NP-40, 4% BSA in PBS for 30 min, and then
 .with either anti-fucosyl GM1 mAb 1:30 or anti-hu-
 .man blood group B antigen mAb 1:15 . After wash-
ing, the cells were incubated with biotin-conjugated
 .anti-mouse IgM antibody 1:100 and then with the
Fig. 2. Thin-layer chromatograms of gangliosides extracted from
GH cells incubated with and without hormones. Gangliosides3
isolated from both untreated GH cells and hormone-treated GH3 3
cells were analyzed by thin-layer chromatography and staining
 .with orcinolrH SO reagent. A The plates were developed2 4
with chloroformrmethanolr5 N ammoniar0.4% CaCl 2
 .55:50:4:6, vrvrvrv . Lanes 2–4, mono-, di-, and tri-sialogang-
lioside from untreated cells, respectively; lanes 5–7, mono-, di-,
tri-sialoganglioside from hormonal-treated cells, respectively.
Lane 1, mouse brain ganglioside standards. The asterisks indicate
 .minor components. B The relative densities of FG1 and FG2
were measured using the software NIH Image on a Macintosh
computer. ) and )) represent minor mono- and di-sialoganglio-
side components, respectively.
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avidin–biotin complex solution Vectorstain ABC
.kit . DiaminobenzidinerH O was used for develop-2 2
ment.
3. Results
3.1. Hormone treatment changed the morphological
and physiological characteristics of the GH cells3
The cells of the untreated population were pre-
dominantly spherical in shape, whereas the cells ex-
posed to a combination of E , EGF and insulin for 42
days had become elongated and flattened Fig. 1A
.and C . Immunocytochemical analyses revealed an
increased proportion of PRL-positive cells among the
hormone-treated GH cells. About 30% of the hor-3
mone-treated GH cells were PRL-positive; the rest3
of cells were also flattened, but were PRL-negative
 .Fig. 1B and D . These observations are consistent
with results for the GH C cell line reported by4 1
w xScammell et al. 8 .
3.2. Changes in GH cell gangliosides induced by3
differentiation
Ganglioside fractions were isolated by DEAE-Sep-
hadex A-25 chromatography. Mono-, di-, and tri-
Fig. 3. Thin-layer chromatograms of glycolipid products cleaved
from gangliosides, extracted from GH cells, by Arthrobacter3
ureafaciens neuraminidase treatment. Plate A: lane 1, ganglio-
sides from mouse brain; lanes 2 and 3, authentic GM1 glycolyl-
.sialic acid before and after neuraminidase treatment, respec-
 .tively; lanes 4 and 5, authentic GM1 acetyl-sialic acid before
and after neuraminidase treatment, respectively; lanes 6 and 7,
gangliosides from GH cells cultured with additives, before and3
 .after neuraminidase treatment, respectively. a N-glycolyl sialic
 .acid, b N-acetyl sialic acid. Plate B: lane 1, gangliosides from
mouse brain; lane 2, neutral glycolipid standard; lane 3, paraglo-
boside; lanes 4 and 5, gangliosides from GH cells cultured with3
additives, before and after neuraminidase treatment, respectively;
 .lanes 6 and 7, authentic GM1 glycolyl-sialic acid before and
after neuraminidase treatment, respectively; lanes 8 and 9, au-
 .thentic GM1 acetyl-sialic acid before and after neuraminidase
treatment, respectively. The plates were developed with chloro-
 .form:methanol:5 N ammonia:0.4% CaCl 55:50:4:6, vrvrvrv ,2
 .and then stained with resorcinolrHCl reagent A and
 .orcinolrH SO reagent B .2 4
sialogangliosides were eluted with 0.05 M, 0.15 M,
and 0.45 M ammonium acetate, respectively. The
amount of mono-sialogangliosides appeared to be
increased by the hormonal treatment, as shown in
Fig. 2. Two major bands were observed in the
mono-sialoganglioside fraction under each set of con-
ditions, and the upper and lower bands were tenta-
tively designated FG1 and FG2, respectively Fig.
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.2A . The quantitative measurements analyzed using
NIH Image indicated that the concentrations of FG1
and FG2 in the hormone-treated cells were more than
twice those of the untreated cells, whereas the ratio of
FG1 to FG2 in each preparation was almost the same.
Thus, expression of both FG1 and FG2 was enhanced
equally by hormonal treatment.
3.3. Structural studies of gangliosides, FG1 and FG2
Treatment with A. ureafaciens neuraminidase in
the presence of detergent liberated free N-
acetylneuraminic acid from FG1 and FG2 and con-
 .verted the gangliosides to neutral glycolipids Fig. 3 .
The sialic acids of FG1 and FG2 were not released
by C. perfringens neuraminidase without detergent
 .data not shown . Together, these results indicate that
FG1 and FG2 contain one mole of N-acetyl-neu-
raminic acid attached not to the terminal position but
to their inner cores. The neutral glycolipids produced
from FG1 and FG2 did not comigrate with asialo-
GM1, rather both migrated more slowly than asialo-
GM1, suggesting that FG1 and FG2 have longer core
structures than asialo-GM1.
As shown in Fig. 4, in the negative-ion FAB mass
spectra of FG1 and FG2, two major pseudo-molecu-
w xy.lar ions H–H were detected at mrz 1662 and
 .  .1772 Fig. 4A and at 1824 and 1934 Fig. 4B ,
which are consistent with the values calculated for
the proposed structures with C16:0- and C24:1-C18
sphingenine. In these mass spectra, the ions A, B, C,
D, E, F, G and H, which are responsible for the
successive elimination of sugar moieties, were clearly
w xdetected 18 . The predominant oligosaccharide ions,
 .  .a Fig. 4A and b Fig. 4B , corresponding to cleav-
age between galactose and glucose at mrz 979 and
w x1141, were also clearly observed 18 .
The anomeric proton regions of the 1H NMR
spectra of FG1 and FG2 yielded five and six distinc-
 .tive signals, respectively Fig. 5 . Based on the chem-
ical shifts and coupling constants they were assigned
to the anomeric protons of a-Fuc, b-GalNAc, b-Gal,
 .b-Gal inner , and b-Glc in ganglioside FG1 with
relative intensities of approximately 1:1:1:1:1 Fig.
.5A . For ganglioside FG2, an H-1 signal correspond-
Fig. 4. Negative-ion FAB mass spectra and fragmentation diagrams of gangliosides FG1 and FG2 extracted from GH cells.3
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1  .Fig. 5. H NMR spectra 400 MHz of gangliosides FG1 and FG2 extracted from GH cells.3
Fig. 6. TLC immunostaining of GH cell gangliosides. Lane 1, gangliosides from mouse brain; lane 2, authentic fucosyl GM1, lane 3,3
M12 ganglioside which contains B-determinant, lanes 4 and 5, purified gangliosides FG1 and FG2 from GH cells; lane 6, gangliosides3
from GH cells before purification. The plates were developed with chloroformrmethanolr5 N ammoniar0.4% CaCl 55:50:4:6,3 2
.vrvrvrv . Plate A was stained with resorcinolrHCl reagent. Plates B and C were immunostained with monoclonal antibodies to fucosyl
 .GM1 CRD73-6 and human blood group B antigen, respectively.
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ing to a terminal a-Gal was observed, in addition to
 .the signals observed for FG1 Fig. 5B . From the
above data, the structures of FG1 and FG2 were
determined to be as follows:
FG1 Fucosyl-GM1 NeuAc . .
XGalb 1 -3GalNAcb 1- 4Galb 1 -4Glcb 1-1 Cer
2 3
< <
Fuc a 1 NeuAc a 2
FG2 a Gal,fucosyl-GM1 NeuAc . .
XGala1- 3Galb 1 -3GalNAcb 1- 4Galb 1 -4Glcb 1-1 Cer
2 3
< <
Fuc a 1 NeuAc a 2
The TLC plates were immunostained using both
anti-human blood group B antigen mAb and anti-
 .  .fucosyl GM1 mAb CRD73-6 Fig. 6 . FG2 was
positive for anti-human blood group B antigen, but
 .negative for fucosyl GM1 Fig. 6C . FG1, on the
other hand, was positive for fucosyl GM1 and nega-
 .tive for human blood group B antigen Fig. 6B .
These results support the results obtained by FAB
mass spectrometry and NMR.
3.4. Flow cytometric analysis of GH cells3
To confirm that these fucogangliosides were ex-
pressed on the cell surface, flow cytometric analyses
of untreated and hormone-treated GH cells were3
performed with both CRD73-6 and anti-human blood
 .group B antigen mAb Fig. 7 . Statistical analyses
indicated that 37.0% of the GH cells were human3
blood group B antigen-positive and 35.7% were fuco-
syl GM1-positive. The amount of each antigen on the
surface of individual cells varied greatly in both cell
preparations, suggesting that GH cells are heteroge-3
neous in terms of expression of these fucoganglio-
sides. Unexpectedly, the signals on the cell surface of
the hormone-treated GH cells were equivalent3
strength to those of the untreated cells. This finding
was inconsistent with the results of the TLC compari-
son of gangliosides extracted from untreated and
hormone-treated GH cells.3
3.5. Immunocytochemistry
To solve the conflict between the TLC data and
flow cytometry data, fixed and permeabilized GH 3
Fig. 7. Flow cytometric analyses of live GH cells. Live GH cells dispersed by trypsin treatment were stained with either anti-human3 3
 .  .blood group B antigen mAb B and E or CRD73-6 C and F , and subjected to analytical flow cytometry. FL1 indicates the log
 .  .fluorescent intensity of each antibody. A–C untreated GH cells, D–F hormone-treated GH cells. GH cells were stained with3 3 3
 .anti-mouse IgM A and D as a negative control.
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Fig. 8. Immunocytochemistry of fixed and permeabilized GH cells. GH cells were cultured on round plastic coverslips. Both untreated3 3
cells and hormone-treated cells were fixed with cold acetone, permeabilized with PBS containing NP-40, and processed for immunocyto-
 .  .chemistry as described in Section 2. A untreated GH cells stained with anti-human blood group B antigen mAb, B hormone-treated3
 .  .GH cells stained with anti-human blood group B antigen mAb, C untreated GH cells stained with CRD73-6, D hormone-treated3 3
GH cells stained with CRD73-6. Magnification, =650.3
cells from both culture conditions were stained with
anti-human blood group B antigen mAb and CRD73-
6. In hormone-treated GH cells, pronounced staining3
of the nuclear envelope and perinuclear area with
anti-human blood group B antigen mAb was ob-
served in almost all of the cells in addition to plasma
 .membrane staining Fig. 8B . In untreated GH cells,3
on the other hand, plasma membrane staining was
predominant in most of the cells, though punctate
staining inside the cells was also observed. The total
strength of the signal was lower in untreated cells
 .than in hormone-treated cells Fig. 8A . CRD73-6
yielded similar results, although the signals were
weak because of the low level of fucosyl GM1 in
 .both cell preparations Fig. 8C and D . Thus, the
increases in these fucogangliosides observed by the
TLC method reflect quantitative changes inside the
cells. Treatment of fixed cells with chloro-
 .formrmethanol 1:1 , which extracts glycosphin-
golipids, prior to staining with anti-human blood
group B antigen mAb and CRD73-6, resulted in the
loss of staining, suggesting that the antigens were
present on glycosphingolipids rather than on glyco-
proteins.
4. Discussion
We have determined the structure of two major
gangliosides of GH cells, fucosyl GM1 and a Gal–3
fucosyl GM1. Although several studies using mAbs
raised against cell surface structures, and our own
 .preliminary data data not shown , have indicated the
presence of many different gangliosides in the ante-
w xrior pituitary gland 9,10,21,22 , the ganglioside com-
position in GH cells was found to be relatively3
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simple. Flow cytometric analysis showed that only
about 30% of GH cells have these fucogangliosides3
on their surface, indicating that the expression of
fucogangliosides on GH cells is heterogeneous in3
the same way that cell size, cell granularity and basal
w xrelease of hormones vary from cell to cell 23,24 .
Expression of fucogangliosides, which contain fu-
cose residues in their structure, is known to increase
in PC12 pheochromocytoma cells in response to nerve
 . w xgrowth factor NGF 18,25,26 . Two of the fucogan-
gliosides expressed by PC 12 cells are
2 3 3 IV Fuca ,IV Gala , II NeuAc–GgOse Cer a Gal–4
.fucosyl GM1 which has human blood group B deter-
minant and which was initially identified as a tumor-
w xassociated antigen in rat hepatoma 27 , and fucosyl
GM1, which is widely distributed in mammalian
w xtissues 28–30 . The functions of these fucoganglio-
sides are still unknown. Hormonal treatment of GH 3
cells increased expression of the fucogangliosides
fucosyl GM1 and a Gal–fucosyl GM1 by about three
fold. NGF is known to induce cellular differentiation
of PC12 cells. NGF increases new fucosyl GM1 and
a Gal–fucosyl GM1 synthesis three fold in PC12
w xcells 18,25,26 , and NGF-dependent induction of
glycosyltransferase activity has also been observed in
w xPC12 cells 31 . Our findings, combined with those
w xof previous reports 18,25,26,31 , suggest that there is
a relationship between increased expression of fuco-
gangliosides and cell differentiation.
Glycosphingolipids have been thought to occur
predominantly in the outer leaflet of the plasma
membrane, and discussions of their functions have
focused on the cell surface area, such as their interac-
w xtions with receptors and cell adhesion molecules 1 .
Our flow cytometry study, in which each antibody
stained only the cell surface antigens of live GH 3
cells, did not support the idea that an increase in
ganglioside expression occurs on the cell surface.
Immunocytochemistry of fixed and permeabilized
GH cells revealed an increase in fucoganglioside3
inside the cells, in the perinuclear area and especially
on the nuclear envelope, rather than on the cell
surface. Recent reports have demonstrated various
subcellular localizations of glycosphingolipids, in-
cluding association with the Golgi membrane and
w xintermediate filaments 32–34 . Furthermore, it has
been suggested that intracellular glycosphingolipids
have a role in sorting vesicles to the apical plasma
w xmembrane in epithelial cells 35,36 . Intracellular ex-
pression of a Gal–fucosyl GM1 and fucosyl GM1 in
differentiated GH cells may play a role in traffick-3
ing the PRL-containing granules to the plasma mem-
brane.
w xWu et al. 37 provided evidence of enhanced
GM1 expression on the nuclear envelope of Neuro-2a
neuroblastoma cells during neuraminidase-induced
neuronal differentiation. They also reported that ex-
ogenous GM1 alters Ca2q regulatory mechanisms in
w x w xthe nucleus 38 . In addition, Katoh et al. 39 demon-
 .strated that protein kinase C PKC in the nuclei of
bovine mammary gland cells, is inhibited by ganglio-
sides GM3, GD3, and GT1b and by two other
unidentified gangliosides, which are presumed to be
present in the nuclei. PKC mediates the transfer of
extracellular signals evoked by hormones or growth
factors to intracellular organelles by phosphorylating
w xits substrate proteins 40 . The enhanced intracellular
expression of fucosyl GM1 and a Gal–fucosyl GM1,
which have structures related to that of GM1, in
differentiated GH cells may be necessary for the3
initiation andror maintenance of their differentiation,
presumably acting by on the nuclear envelope in a
PKC-dependent manner.
Our knowledge of the differentiation of anterior
pituitary cell types is currently based on immunohis-
tochemical studies of the hormones they produce.
Focusing on ganglioside expression may give us new
insights into the ontogenic development and cellular
differentiation of the anterior pituitary gland. In addi-
tion, the model system using the GH cell line should3
be useful for studying the functions of gangliosides
inside the cells.
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